Join PfizerLink — a clinical research registry
Get notified about Pfizer clinical trials that may be right for you — now and over time.
Visit PfizerLink
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults:
Closest Location
Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.
Condition
Lower Respiratory Tract Illness
Sex
Male or Female
Age
60+ years